Recruitment

Recruitment Status
Completed
Estimated Enrollment
500

Inclusion Criterias

Urine protein <2+ (dipstick)
Previous hormonotherapy for metastatic Breast Cancer is allowed
Life expectancy of ≥12 weeks
...
Urine protein <2+ (dipstick)
Previous hormonotherapy for metastatic Breast Cancer is allowed
Life expectancy of ≥12 weeks
Adequate haematological, renal and hepatic function
ECOG performance status ≤2
Written informed consent
No prior first line treatment for metastatic Breast Cancer
One or more measurable lesions (≥1cm in diameter with spiral CT scan or ≥2cm with conventional techniques) according to RECIST criteria
Age ≥18 years
Patients with histologically or cytologically confirmed, HER2-negative, metastatic Breast Cancer

Exclusion Criterias

Presence or history of other neoplasm except properly treated basal cell skin cancer or in situ cervical carcinoma
Patients participating in interventional clinical trial
Patients with brain metastases and/or cancerous meningitis
...
Presence or history of other neoplasm except properly treated basal cell skin cancer or in situ cervical carcinoma
Patients participating in interventional clinical trial
Patients with brain metastases and/or cancerous meningitis
Previous first line treatment for metastatic colorectal cancer(progression >12 months after the end of adjuvant treatment)
Previous radiotherapy to target lesions

Summary

Conditions
Metastatic Breast Cancer
Type
Observational
Design
Observational Model: Cohort

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

Nowadays in clinical practice patients with previously untreated metastatic breast cancer often receive taxane-based chemotherapy (paclitaxel or docetaxel) in combination with bevacizumab as it has been shown to increase progression-free survival. There is currently minimal information whether bevac...

Nowadays in clinical practice patients with previously untreated metastatic breast cancer often receive taxane-based chemotherapy (paclitaxel or docetaxel) in combination with bevacizumab as it has been shown to increase progression-free survival. There is currently minimal information whether bevacizumab should be given as maintenance therapy after discontinuation of chemotherapy.

Inclusion Criterias

Urine protein <2+ (dipstick)
Previous hormonotherapy for metastatic Breast Cancer is allowed
Life expectancy of ≥12 weeks
...
Urine protein <2+ (dipstick)
Previous hormonotherapy for metastatic Breast Cancer is allowed
Life expectancy of ≥12 weeks
Adequate haematological, renal and hepatic function
ECOG performance status ≤2
Written informed consent
No prior first line treatment for metastatic Breast Cancer
One or more measurable lesions (≥1cm in diameter with spiral CT scan or ≥2cm with conventional techniques) according to RECIST criteria
Age ≥18 years
Patients with histologically or cytologically confirmed, HER2-negative, metastatic Breast Cancer

Exclusion Criterias

Presence or history of other neoplasm except properly treated basal cell skin cancer or in situ cervical carcinoma
Patients participating in interventional clinical trial
Patients with brain metastases and/or cancerous meningitis
...
Presence or history of other neoplasm except properly treated basal cell skin cancer or in situ cervical carcinoma
Patients participating in interventional clinical trial
Patients with brain metastases and/or cancerous meningitis
Previous first line treatment for metastatic colorectal cancer(progression >12 months after the end of adjuvant treatment)
Previous radiotherapy to target lesions

Locations

Athens
Piraeus
Alexandroupolis
Athens
Heraklion, Crete
...
Athens
Piraeus
Alexandroupolis
Athens
Heraklion, Crete
Thessaloniki

Tracking Information

NCT #
NCT01978977
Collaborators
Not Provided
Investigators
  • Principal Investigator: Vassilis Georgoulias, MD Hellenic Oncology Research Group
  • Vassilis Georgoulias, MD Hellenic Oncology Research Group